LENZ Therapeutics, Inc. (LENZ) Q3 FY2026 earnings

Reported results

• Q3 2026 GAAP net product sales were $2.6 million, compared to $0 in Q3 2025.
• Q3 2026 GAAP license revenue was $0.8 million, compared to $12.5 million in Q3 2025.
• Q3 2026 GAAP SG&A expenses were $35.8 million, including $4.1 million in non-cash stock-based compensation expense.
• Q3 2026 GAAP net loss was $31.0 million, or $0.99 per basic and diluted share.
• Cash, cash equivalents and marketable securities were $197.3 million as of September 30, 2026.

Guidance

• The strategic reorganization is expected to reduce projected 2027 annualized operating expenses by more than 50%.
• The company is targeting approximately $70 million to $75 million in 2027 operating expenses, excluding stock-based compensation.
• Reorganization activities are anticipated to be completed during Q4 2026 with an estimated $5 million in one-time net restructuring charges.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-28 (8-K, Item 2.02). Read the original filing on sec.gov.